Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | BUB1 | O43683 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9394261 | 0.79 | TSHR (0.48) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL1613917 | 0.79 | TSHR (0.48) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL15927876 | 0.78 | CTSL (0.43) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL9813742 | 0.78 | CTSL (0.46) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL25631052 | 0.77 | TAAR1 (0.47) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL599216 | 0.77 | TSHR (0.45) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL15927873 | 0.76 | CTSL (0.51) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL31715587 | 0.76 | CTSL (0.42) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL1928095 | 0.76 | TSHR (0.58) | CTSLCTSBCTSKTSHRNAAA | |
| SCHEMBL17019782 | 0.76 | TSHR (0.58) | CTSLCTSBCTSKTSHRNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720847-A1 | HISTAMINE-3 RECEPTOR MODULATORS | Pfizer Products Incorporated (US) | 2006-11-15 | — | — | EP | disclosed |
| US-7115600-B2 | Histamine-3 receptor modulators | PFIZER INC. (US) | 2006-10-03 | — | — | US | disclosed |
| WO-2005080361-A1 | HISTAMINE-3 RECEPTOR MODULATORS | PFIZER PRODUCTS INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171181-A1 | 3-Benzyloxymethyl-1-(4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanol for example; treating allergies and mood disorders; use in combination with a histamine H1 antagonist or a neurotransmitter re-uptake blocker | HRH3, HRH4, HRH1 | CTSL 986/4885CTSB 186/4885CTSK 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.